MedPath

Comparison of Dienogest with medroxyprogesterone acetate in the treatment of pelvic pain and recurrent endometriosis

Phase 3
Recruiting
Conditions
Endometriosis.
Endometriosis
Registration Number
IRCT20170917036227N5
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
130
Inclusion Criteria

Women aged 18-45 years old
Endometriosis confirmation via laparoscopy and histopathologic assessmnet

Exclusion Criteria

Pregnancy or Breast Feeding
Plan to become pregnant
Amenorrhea (no more menstruation - equal to 3 months in the last 6 months)
Undiagnosed genital bleeding
Recent use of hormonal agents
Contraindications to the use of progesterone
Having a risk factor for decreased bone density
Use of acitretin, anticoagulants such as warfarin, antidiabetic drugs, aperitif and, artemether, atazanavir, barbiturates, bexarotene, Boceprevir, bosentan, thrombogenic drugs, clobazam, anticonvulsant drugs (carphenazine, Topiramate, valproic acid, lamotrigine, phenytoin ...), Darunavir, Deferasirox, Efavirenz, Felbamate, Griseofulvin, Mifepristone, Nelfinavir, Neuruppin, Selegiline, Thalidomide, Tranexamic Acid and Voriconazole

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath